Start Date
March 31, 2012
Primary Completion Date
June 30, 2015
Study Completion Date
September 30, 2015
90Y-hPAM4
90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
90Y-hPAM4
90Y-hPAM4 + gemcitabine
Weill Cornell NY Presbyterian Hospital, New York
Mt. Sinai Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Hillman Cancer Center, Pittsburgh
Kimmel Cancer Center at Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
Christiana Care Health Services Helen Graham Cancer Center, Newark
VA Oncology Associates, Norfolk
University of North Carolina Medical Center, Chapel Hill
Institute of Translational Oncology Research, Greenville
Winship Cancer Institute, Atlanta
Sylvester Comprehensive Cancer Center Univ. Miami, Miami
Jackson North Medical Center, Miami
Moffitt Cancer Center, Tampa
Ohio State University Medical Center, Columbus
Goshen Center for Cancer Care, Goshen
Detroit Clinical Research Center, Detroit
St. Mary's Trinity Healthcare, Grand Rapids
Tyler Cancer Center, Tyler
Mountain States Tumor Institute, Boise
Banner Healthcare, Gilbert
Scottsdale Healthcare, Scottsdale
New Mexico Cancer Care Alliance, Albuquerque
Virginia Mason Medical Center, Seattle
Lead Sponsor
Gilead Sciences
INDUSTRY